Developing effective and mechanism-based combination therapy regimens is essential to maximizing the efficacy of RAF/MEK/ERK pathway inhibition, which holds great promise for pancreatic cancer control. The gene discussed is RAF1; the disease is familial pancreatic carcinoma.